Table 1 Patient characteristics and baseline data
From: Receptor conversion and survival in breast cancer liver metastases
n (%) | |
|---|---|
Cohort | 132 |
Gender (female/male) | 132/0 (100/0) |
Median Age at BC (years) | 60 (27–84) |
Tumor size BC | |
0 | 10 (7.9) |
1 | 38 (30.2) |
2 | 62 (49.2) |
3 | 12 (9.5) |
4 | 4 (3.2) |
Lgllmet BC | |
0 | 86 (67.7) |
1 | 37 (29.1) |
2 | 2 (1.6) |
3 | 2 (1.6) |
Met BC | |
No | 132 (100.0) |
Yes | 0 (0.0) |
ER BC | |
Negative | 94 (71.2) |
Positive | 38 (28.8) |
PgR BC | |
Negative | 57 (43.8) |
Positive | 73 (56.2) |
HER2 BC | |
Negative | 17 (13.8) |
Positive | 106 (86.2) |
Vascular invasion | |
No | 33 (32.0) |
Yes | 70 (68.0) |
NHG | |
1 | 4 (3.2) |
2 | 47 (37.9) |
3 | 73 (58.9) |
Extrahepatic metastases at time of BCLM | 53 (40.2) |
Surgery for BCLM | 15 (11.4) |
Median time BC to BCLM (months) | 31 (1–219) |
Adjuvant endocrine therapy (BC) | 81/116 (69.8) |
Adjuvant chemotherapy (BC) | 73/117 (62.4) |
Adjuvant target therapy (BC) | 10/117 (8.5) |